Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T cell infiltrate in the bone marrow

Mechanisms of in vivo AML response and resistance to chemotherapy remain poorly characterized. To determine whether response to lenalidomide might share features with response to other forms of chemotherapy, we applied immunohistochemistry and gene panel sequencing to serial samples from a patient